Another reason for this higher rate of adverse cardiovascular outcomes could be a greater prevalence of a family history of coronary artery disease in insulin-treated DM patients and a lesser prevalence of hyperlipidemia in non-insulin treated DM patients shown in the study conducted by Kirtane in 2009 [16]. This evidence concerns the gene INS and coronary artery disorder.